Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-1.84%
+1.11%
-0.22%
+0.32%
+28.68%
NVO
Novo Nordisk A/S Com
$69.64
Chart
$68.17 (+2.16%)
$65.09 (+6.99%)
$89.55 (-22.23%)
$131.54 (-47.06%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.84%
+1.11%
-0.22%
+0.32%
+28.68%
NVO
Novo Nordisk A/S Com
Current Price
$69.64
Buy
Login to view Novo Nordisk A/S Com (NVO) recommendation from the last 90 days from financial news and social media.
Chart
$68.17 (+2.16%)
$65.09 (+6.99%)
$89.55 (-22.23%)
$131.54 (-47.06%)
NVO Latest Analysis
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval. ) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new higher Wegovy (subcutaneous semaglutide 7.2 mg).The submission is based on clinical data from the STEP UP and STEP UP T2D trials investigating the efficacy and safety of semaglutide 7.2 mg in adults with obesity in STEP UP and adults with obesity and type 2 diabetes in STEP UP T2D.In
Today
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.
Mon Jul 7, 2025
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits. ) is currently experiencing a decline in its stock price trading lower on Monday. The company’.s stock has plummeted approximately 18% over the past month reflecting recent challenges.A significant development contributing to this decline occurred in June 2025 when ) ended its collaboration with Hims &. Hers. Consequently Hims &. Hers will no longer have direct access to Wegovy Novo Nordisk’.s popular GLP-1 weig
Mon Jul 7, 2025
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report. ) executives allegedly ignored internal warnings that the company was unprepared to launch its .As rival ) Zepbound gains momentum the Danish pharmaceutical giant is grappling with the fallout of those early decisions.Wegovy approved in the United States in mid-2021 marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.Also Read: But the company has struggled to k
Tue Jul 1, 2025
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever.
Tue Jul 1, 2025
Novo Nordisk continues efforts to support patient access to authentic FDA approved Wegovy® and prioritize patient safety. Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living...
Thu Jun 26, 2025
Why Hims & Hers Stock Is Crashing and Is It a Buying Opportunity?. Novo Nordisk (NYSE: NVO) severed its partnership with Hims &. Hers (NYSE: HIMS) arguing that the company breached the agreement between the two.
Thu Jun 26, 2025
After Its Biggest Drop Ever...Is HIMS A Buy?. HIMS just suffered the biggest single-day drop in its trading history a
Wed Jun 25, 2025
Novo Nordisk stock falls after Spain probes obesity awareness campaign.
Wed Jun 25, 2025
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?. NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy hitting patient access and market share plans.
Tue Jun 24, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings